Shares Up 3.27% TodayCompany is Adding Technology for the Next Round of Trials
Recently, I read that CBLI selected the InSpire reporting tool from PharmaVigilant for its upcoming Phase II trial.
"We chose InSpire because it provides us unprecedented access to our data, not only during the trial but throughout our development program. The I- Warehouse reporting tool offers us the access to our data that we need during our early stages of development." said John Gordon, Director Clinical Development for Cleveland Biolabs.
I-Warehouse includes access to the InSpire Reporting Tool, the only ad hoc reporting tool in the industry that provides Sponsors with the ability to query their data both within and across trials. With the proprietary Health Information Protection Key (HIP Key), Sponsors can view their patients' data across multiple trials and programs without affecting participant confidentiality.
PharmaVigilant offers unique solutions to address the complexities of global clinical research. The Company focuses on Phase 2-4 clinical trials, registries and other post-marketing studies. The InSpire solution supports over 200,000 patients in 14 countries in North America and Europe, and incorporates the latest single platform,